How much European prescribing physicians know about invasive fungal infections management?
Authors:
- Maricela ValerioMaricela Valerio
- Antonio VenaAVAntonio Vena
- Emilio BouzaEBEmilio Bouza
- Nanna ReiterNRNanna Reiter
- Pierluigi VialePVPierluigi Viale
- Marcel HochreiterMHMarcel Hochreiter
- Maddalena GiannellaMaddalena Giannella
- Patricia MuñozPMPatricia Muñoz
- on behalf the COMIC study group (Collaborative group on Mycosis)OMon behalf the COMIC study group (Collaborative group on Mycosis)
Open Access
- 21 February 2015
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 80
Abstract
The use of systemic antifungal agents has increased in most tertiary care centers. However, antifungal stewardship has deserved very little attention. Our objective was to assess the knowledge of European prescribing physicians as a first step of an international program of antifungal stewardship. Staff physicians and residents of 4 European countries were invited to complete a 20-point questionnaire that was based on current guidelines of invasive candidiasis and invasive aspergillosis. 121 physicians (44.6% staff, 55.4% residents) from Spain 53.7%, Italy 17.4%, Denmark 16.5% and Germany 12.4% completed the survey. Hospital departments involved were: medical 51.2%, ICUs 43%, surgical 3.3% and pharmaceutical 2.5%. The mean score of adequate responses (± SD) was 5.8 ± 1.7 points, with statistically significant differences between study site and type of physicians. Regarding candidiasis, 69% of the physicians clearly distinguished colonization from infection and the local rate of fluconazole resistance was known by 24%. The accepted indications of antifungal prophylaxis were known by 38%. Regarding aspergillosis, 52% of responders could differentiate colonization from infection and 42% knew the diagnostic value of galactomannan. Radiological features of invasive aspergillosis were well recognized by 58% of physicians and 57% of them were aware of the antifungal considered as first line treatment. However, only 37% knew the recommended length of therapy. This simple, easily completed questionnaire enabled us to identify some weakness in the knowledge of invasive fungal infection management among European physicians. This survey could serve as a guide to design a future tailored European training program.Keywords
This publication has 48 references indexed in Scilit:
- Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently neededJournal of Antimicrobial Chemotherapy, 2014
- ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patientsClinical Microbiology and Infection, 2012
- Adherence to recommendations for the use of antifungal agents in a tertiary care hospitalJournal of Antimicrobial Chemotherapy, 2012
- Systemic antifungal therapy in critically ill patients without invasive fungal infection*Critical Care Medicine, 2012
- Impact of Education and an Antifungal Stewardship Program for Candidiasis at a Thai Tertiary Care CenterInfection Control & Hospital Epidemiology, 2010
- Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Inappropriate Use of Antifungal Medications in a Tertiary Care Center in Thailand: A Prospective StudyInfection Control & Hospital Epidemiology, 2008
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial StewardshipClinical Infectious Diseases, 2007
- Significance of the Isolation of Candida Species from Respiratory Samples in Critically Ill, Non-neutropenic PatientsAmerican Journal of Respiratory and Critical Care Medicine, 1997